AmerisourceBergen Technology Group Opens New Facility in Buffalo Grove, Illinois
"Our new Buffalo Grove facility reinforces our commitment to providingworld-class pharmacy automation and continuously improving the quality of ourproducts and services," said Pete Gilbert, Group Vice President of Operationsfor AmerisourceBergen Technology Group.
The ribbon-cutting ceremony participants included U.S. Representative MarkKirk, State Representative Kathleen Ryg, and Buffalo Grove City Manager BillBrimm.
The AmerisourceBergen Technology Group partners with pharmacies to improveefficiency through technology. Across all pharmacy markets and sizes, ABTGcustom-designs solutions with advanced pharmacy automation, prescriptionfulfillment and distribution systems.
AmerisourceBergen is one of the world's largest pharmaceutical servicescompanies serving the United States, Canada and selected global markets.Servicing both pharmaceutical manufacturers and healthcare providers in thepharmaceutical supply channel, the Company provides drug distribution andrelated services designed to reduce costs and improve patient outcomes.AmerisourceBergen's service solutions range from pharmacy automation andpharmaceutical packaging to reimbursement and pharmaceutical consultingservices. With more than $64 billion in annual revenue, AmerisourceBergen isheadquartered in Valley Forge, PA, and employs more than 11,500 people.AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information,go to www.amerisourcebergen.com.
This news release may contain certain "forward-looking statements" withinthe meaning of Section 27A of the Securities Act of 1933 and Section 21E ofthe Securities Exchange Act of 1934. These statements are based onmanagement's current expectations and are subject to uncertainty and changesin circumstances. Actual results may vary materially from the expectationscontained in the forward-looking statements. The following factors, amongothers, could cause actual results to differ materially from those describedin any forward-looking statements: competitive pressures; the loss of one ormore key customer or supplier relationships; customer defaults orinsolvencies; changes in customer mix; supplier defaults or insolvencies;changes in pharmaceutical manufacturers' pricing and distribution policies orpractices; adverse resolution of any contract or other disputes with customers(including departments and agencies of the U.S. Government) or suppliers;regulatory changes (including increased government regulation of thepharmaceutical supply channel); government enforcement initiatives (including(i) the imposition of increased obligations upon pharmaceutical distributorsto detect and prevent suspicious orders of controlled substances (ii) thecommencement of further administrative actions by the U. S. Drug EnforcementAdministration seeking to suspend or revoke the license of any of theCompany's distribution facilities to distribute controlled substances, or(iii) the commencement of any enforcement actions by any U.S. Attorneyalleging violation of laws and regulations regarding diversion of controlledsubstances and suspicious order monitoring); changes in U.S. governmentpolicies (including reimbursement changes arising from federal legislation,including the Medicare Modernization Act and the Deficit Reduction Act of2005); changes in regulatory or clinical medical guidelines an
You May Also Like